vimarsana.com

Page 96 - பல்கலைக்கழகம் ஆஃப் டெக்சாஸ் ம்ட் ஆண்டர்சன் புற்றுநோய் மையம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Wren Therapeutics Announces Financing of 12 4 Million (c $17 0 Million)

Posted on 7440 Wren Therapeutics Ltd., (“Wren”), a biopharmaceutical company pioneering a unique network kinetics approach to drug discovery for protein misfolding diseases, today announced the closing of a £12.4 million (c. $17.0 million) financing. This financing brings the total capital raised to date to approximately £33 million (c. $45 million). The financing was led by existing shareholder The Baupost Group, with participation from existing investors including LifeForce Capital and new investors including Schooner Capital and Industry Ventures. Dr. Samuel Cohen, Chief Executive Officer of Wren, commented: “This support from both our existing as well as our new shareholders will accelerate the advancement of our two lead small molecule programs towards the clinic for the potential treatment of Alzheimer’s disease and various synucleinopathies including Parkinson’s disease.”

Wren Therapeutics Announces Financing of £12 4 Million (c $17 0 Million)

Press release content from Business Wire. The AP news staff was not involved in its creation. Wren Therapeutics Announces Financing of £12.4 Million (c. $17.0 Million) January 25, 2021 GMT CAMBRIDGE, United Kingdom (BUSINESS WIRE) Jan 25, 2021 Wren Therapeutics Ltd., (“Wren”), a biopharmaceutical company pioneering a unique network kinetics approach to drug discovery for protein misfolding diseases, today announced the closing of a £12.4 million (c. $17.0 million) financing. This financing brings the total capital raised to date to approximately £33 million (c. $45 million). The financing was led by existing shareholder The Baupost Group, with participation from existing investors including LifeForce Capital and new investors including Schooner Capital and Industry Ventures.

Moody mergers: Ruth and Paul SoRelle

Celebrating love for a lifetime Ruth and Paul SoRelle met as journalism students working at The Daily Texan. “I was on the copydesk, and he came in (to the newsroom) to schmooze with the copy chief,” Ruth recalled. “Paul was (still in school) and also with the Long News Service covering the Legislature. I remember he had on a suit – an usual form of dress in the late 1960s.” Initially friends, they started dating and eventually announced their marriage engagement to their families, which prompted a “heated discussion on the wedding and arrangements,” Paul said. “We decided that we just wanted to get married, so we got a license and arranged for a Travis County judge to marry us,” Paul said. “I let my roommates know that we were going to wed. They put the announcement on the blackboard in The Daily Texan office. On April 10, 1970, we ended up having one of the largest elopements that spring at the Travis County Courthouse.”

Immunotherapy Is the Next Wave in Cancer Treatment How Effective Is It?

Immunotherapy Is the Next Wave in Cancer Treatment. How Effective Is It? Prevention 1/24/2021 Beth Howard © Meletios Verras - Getty Images The goal of immunotherapy is to teach the immune system to recognize and kill cancer cells, but how does it work? And is it effective? Here’s the latest. For decades, the most effective treatments for cancer have involved surgery and rounds of chemotherapy or radiation. But some of those treatments can harm healthy cells, which is why advancements that harness the power of the immune system are a big deal. “Some patients have truly remarkable responses to immunotherapy that last for years in some cases so many years that we think these patients may even be cured of their disease,” says Ezra Cohen, M.D., codirector of the Precision Immunotherapy Clinic at UC San Diego Health. This therapy doesn’t work for every cancer yet, but here’s the latest:

Researchers identify genetic risk factors contributing to pneumonia susceptibility and severity

Researchers identify genetic risk factors contributing to pneumonia susceptibility and severity Researchers at Vanderbilt University Medical Center and colleagues have identified genetic factors that increase the risk for developing pneumonia and its severe, life-threatening consequences. Their findings, published recently in the American Journal of Human Genetics, may aid efforts to identify patients with COVID-19 at greatest risk for pneumonia, and enable earlier interventions to prevent severe illness and death. Despite the increasing availability of COVID-19 vaccines, it will take months to inoculate enough people to bring the pandemic under control, experts predict. In the meantime, thousands of Americans are hospitalized and die from COVID-19 each day.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.